Denali Therapeutics Inc. (DNLI) Misses Q2 EPS by 1c

Denali Therapeutics Inc. (NASDAQ: DNLI) reported Q2 EPS of ($0.72), $0.01 worse than the analyst estimate of ($0.71). Revenue for the quarter came in at $0 versus the consensus estimate of $7.47 million.

For earnings history and earnings-related data on Denali Therapeutics Inc. (DNLI) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• DOE To Make $17.5B In Loans Available To Finance Nuclear - WSJ
• Canaf Reports Financial Results for Q2 2026 and Progress on Self-Storage Platform